Abstract
This report uses the SIQR model proposed by Takashi Odagaki to examine the epidemic trend of COVID-19 in nine major countries during February-May 2020, and to clarify the peculiar trend of infection in Japan. The SIQR model, which is an improvement on the conventional SIR model, is unique in that it allows us to theoretically clarify the epidemic phenomenon by separating the number of daily confirmed new cases by testing and the number of infecteds at large who remain untested, and also allows us to theoretically consider measures to control the epidemic. The infection control measures of each country were analyzed by dividing them into three groups according to the size of the decay (or growth) rate of infected at large (λ). The active group includes China and South Korea, the passive group includes the United States and Sweden, and the average group includes Germany, Italy, France, Spain, and Japan. China and South Korea are the countries with the best testing and quarantine systems, and South Korea in particular having managed to contain the infection without lockdown through early quarantine by thorough testing. On the other hand, the United States and Sweden do not have a well-developed inspection and quarantine system and have shown little restraint in social distancing. In the case of Japan, the following special factors may have contributed to the extreme lack of PCR testing : (1) The “4-day fever rule” established by the Ministry of Health, Labour and Welfare was strictly enforced. (2) Even after the decision to postpone the Olympics, the government continued to monopolize PCR testing for the sake of unified analysis of infection data, and the policy of expanding PCR testing by private companies was not implemented.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
None
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.